Novel non-invasive liver disease assessments (NILDAs) are effective alternatives to liver biopsy for the treatment of liver ...

Assessing the toxicity of food contaminants—including carcinogenic potential—is a major challenge in evaluating the risks ...

Cirrhosis and liver cancer are two of the world’s leading causes of illness and death, but they typically creep up quietly. Most people with liver disease are symptom-free until complications like ...

A blood test looking for five specific proteins can predict metabolic dysfunction-associated steatotic liver disease, more commonly known as fatty liver disease, researchers are scheduled to report at ...

Novel non-invasive liver disease assessments (NILDAs) can effectively replace liver biopsy for assessing liver fibrosis in ...

A clinical trial led by Kirby Institute at UNSW Sydney has found that point-of-care testing for hepatitis B DNA is as ...

Hepatitis C (HCV) is a common but entirely curable disease, yet it’s the leading cause of liver cancer if left untreated. According to the most recent data available, HCV causes more deaths in the U.S ...

A recent study at the Medical University of South Carolina's (MUSC) Digestive Disease Research Core Center (DDRCC) provides insight into why physicians should be cautious when using a certain liver ...